Cryptogenic Stroke - Diagnostic Approach, Hidden Etiologies & Evidence-Based Management

Cryptogenic stroke remains one of the most challenging entities in vascular neurology, accounting for 20–30% of all ischemic strokes even after a standard diagnostic evaluation. With over 200 known causes of ischemic stroke, clinicians must navigate a complex differential that spans cardioembolic sources, large- and small-vessel disease, hypercoagulable states, dissections, vasculitis, and rare or drug-induced etiologies. 

This CME activity provides a structured, clinically grounded approach to the evaluation and management of cryptogenic stroke. Learners will review the contemporary classification of ischemic stroke subtypes, examine the role of advanced vascular imaging, and determine when to escalate to transesophageal echocardiography (TEE) to detect left atrial appendage thrombi, complex aortic plaque, and high-risk PFO/atrial septal aneurysm.

A major focus is on embolic stroke of undetermined source (ESUS)—its criteria, limitations, and the lessons learned from key clinical trials (NAVIGATE ESUS, RESPECT ESUS, ATTICUS, ARCADIA), which collectively demonstrated that empiric anticoagulation with DOACs is not beneficial and may be harmful in this population. 

The course also highlights the impact of prolonged rhythm monitoring using loop recorders, which can reclassify a substantial proportion of cryptogenic strokes as cardioembolic by uncovering occult atrial fibrillation and directly altering secondary prevention strategies.

Through case-based discussion (including recurrent “Florida woman” cryptogenic strokes), practical mnemonics, and real-world data comparing comprehensive vs community stroke centers, clinicians will gain a pragmatic framework to reduce the size of the “cryptogenic” category, refine workups, and individualize treatment.

Educational Objectives

After completing this activity, learners will be able to:

• Differentiate major ischemic stroke subtypes—cardioembolic, large-vessel atherosclerotic, small-vessel (lacunar), and rare causes—within the broader context of cryptogenic stroke.
• Analyze the essential components of a comprehensive cryptogenic stroke workup, including brain imaging, intracranial and extracranial vascular imaging, echocardiography, and rhythm monitoring.
• Interpret evidence from ESUS clinical trials to determine when antiplatelet therapy is preferred over anticoagulation in patients without documented atrial fibrillation.
• Evaluate the clinical utility of short-term patches versus long-term loop recorders for detecting occult atrial fibrillation and guiding secondary prevention strategies.

Who Should Do This Course?

This course is designed for:

• Neurologists involved in stroke care, vascular neurology, and general neurology practice.
• Cardiologists and Cardiac Electrophysiologists evaluating embolic sources, arrhythmias, and cardioembolic mechanisms.
• Emergency Medicine Physicians managing acute ischemic stroke presentations and early diagnostic decisions.
• Hospitalists and Internal Medicine Physicians overseeing inpatient stroke evaluations and secondary prevention.
• Nurse Practitioners, Physician Assistants, Registered Nurses, and Stroke Program Coordinators participating in stroke workups, monitoring, and patient education.
• Neurocritical Care and Acute Care Providers caring for complex cerebrovascular patients.
• Residents and Fellows in neurology, internal medicine, emergency medicine, and cardiology seeking advanced stroke diagnostic training.

Did You Know?

• 80–85% of strokes are ischemic, and the remaining 15–20% are hemorrhagic, yet up to 20–30% of ischemic strokes remain cryptogenic after workup.
• There are over 200 known causes of ischemic stroke, grouped into a few broad categories (cardioembolic, large vessel, small vessel, rare causes, and cryptogenic).
• Cardiogenic sources account for about 25% of ischemic strokes, with atrial fibrillation responsible for roughly half of cardioembolic events.
• Prolonged monitoring with an implantable loop recorder can reclassify about one-third of cryptogenic strokes as AF-related, translating to approximately 9% of all ischemic strokes.
• ESUS trials (NAVIGATE ESUS, RESPECT ESUS, ATTICUS, ARCADIA) showed no reduction in recurrent stroke with DOACs compared with aspirin, and in some cases demonstrated increased major bleeding and mortality.
• Arterial dissection may represent up to 20% of strokes in patients under 45 years, especially in the setting of trauma, chiropractic manipulation, or high-impact sports such as soccer.